Over the past three days, we explored key clinical questions about Telmisartan. Here are the answers along with a concise pharmacology summary.
Question 1
A 56-year-old man with newly diagnosed hypertension has a history of persistent dry cough while taking enalapril. His physician switches him to Telmisartan.
Question:
Why is Telmisartan considered a suitable alternative for this patient?
Answer: B. It blocks angiotensin II (AT₁) receptors without increasing bradykinin levels.
Explanation:
Telmisartan is an Angiotensin II Receptor Blocker (ARB) that selectively blocks the AT₁ receptor, preventing the effects of angiotensin II such as vasoconstriction and aldosterone release. Unlike ACE inhibitors, it does not increase bradykinin levels, making persistent dry cough much less common.
Question 2
A 64-year-old man with hypertension has been taking Telmisartan for three months. During a routine follow-up, his blood tests reveal an electrolyte abnormality, while his kidney function remains stable.
Question:
Which electrolyte abnormality is most commonly associated with Telmisartan?
Answer: A. Hyperkalemia
Explanation:
By reducing aldosterone secretion, Telmisartan decreases potassium excretion by the kidneys, increasing the risk of hyperkalemia. This risk is higher in patients with chronic kidney disease, diabetes or those taking potassium supplements or potassium-sparing diuretics.
Question 3
A 58-year-old woman was switched from enalapril to Telmisartan after developing a persistent dry cough. Two months later, her blood pressure is well controlled, and the cough has resolved.
Question:
Why is cough less common with Telmisartan?
Answer: A. It does not increase bradykinin levels.
Explanation:
Unlike ACE inhibitors, Telmisartan does not inhibit the angiotensin-converting enzyme (ACE) and therefore does not cause bradykinin accumulation. Elevated bradykinin is the primary reason for the persistent dry cough associated with ACE inhibitors. Since Telmisartan selectively blocks AT₁ receptors without affecting bradykinin metabolism. So the risk of cough is significantly lower.
Key Clinical Points
Generic Name: Telmisartan
Class: Angiotensin II Receptor Blocker (ARB)
Mechanism of Action: Selectively blocks AT₁ receptors, inhibiting the effects of angiotensin II, resulting in vasodilation, reduced aldosterone secretion, and lower blood pressure.
Common Indications:
- Hypertension
- Cardiovascular risk reduction in high-risk patients
- Renal protection in selected patients with diabetic nephropathy
Common Adverse Effects:
- Dizziness
- Hyperkalemia
- Hypotension
- Increased serum creatinine
Contraindications:
- Pregnancy
- Hypersensitivity to Telmisartan
- Use with caution in bilateral renal artery stenosis
Remember: Before starting or increasing the dose of Telmisartan, monitor blood pressure, serum potassium and renal function especially in older adults and patients with kidney disease or those receiving potassium-raising medications.
MBH/PS